Slide 1: ChromaDex Earnings Conference Call Fourth Quarter 2024
ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025
Slide 2: Safe Harbor Statement
2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 19
Slide 3: Q4 2024 & Recent Highlights
3 Q4 2024 & Recent Highlights (1) See slide 11 for the non-GAAP reconciliation Delivered record-breaking financial performance in 2024 through strategic initiatives while strengthening our foundation for sustained growth, positioning us for continued success in 2025 and beyond. Fourth Quarter 2024 •
Slide 4: Management Team
4 Management Team Rob Fried Chief Executive Officer E-commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Andrew Shao SVP, Global Regulatory & Scientific Affairs Over two decades of global nutrition industry experience at Amway,
Slide 5: Financial Highlights
Financial Highlights
Slide 6: Q4 2024 Net Sales Mix
6 Q4 2024 Net Sales Mix E-commerce 63% Watson's & Other B2B 20% Food-grade Niagen® 13% Analytical Reference Standards & Services 3% Other Ingredients 1% Q4 2023Q4 2024 • Tru Niagen® net sales decreased to 78% of net sales in Q4 2024 compared to 83% in Q4 2023(1) • Niagen®-related net sales remained
Slide 7: Q4 2024 Net Sales
7 Q4 2024 Net Sales Q4 2024 Net Sales ($ in millions) $22.7 17.3 5.4 4.5 0.8 0.7 0.4 E-commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients Q4 2024 total net sales up 37% year-over-year driven by strong growth in E-
Slide 8: Full Year 2024 Net Sales
58.0 18.8 17.5 1.7 3.0 0.6 E-commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients 8 Full Year 2024 Net Sales FY 2024 Net Sales ($ in millions) Total +19% +13% +3% +66% +4% (2)% YoY % (vs FY 2023) $76.8 2024 total ne
Slide 9: 2023 – 2024 Net Sales Summary
9 2023 – 2024 Net Sales Summary ($ in millions) 2024 2023 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Ecommerce 12.9 13.0 14.8 17.3 58.0 12.2 13.0 12.7 13.3 51.2 Watsons & Other B2B 4.5 5.6 3.3 5.4 18.8 5.4 3.9 4.7 4.3 18.3 Total TRU NIAGEN 17.4 18.6 18.1 22.7 76.8 17.6 16.9 17.4 17.6 69.5 Food-grade
Slide 10: Q4 2024 vs Q4 2023 Key P&L Metrics
10 Q4 2024 vs Q4 2023 Key P&L Metrics (in thousands) Q4 2024 Q4 2023 Notes Net Sales $29,125 $21,196 Tru Niagen® sales increased by 29%, while Niagen ingredient sales grew by 96%, driven by strong Ecommerce performance, increased demand from food-grade ingredient partners, and the launch of pharmace
Slide 11: Adjusted EBITDA Summary
11 Adjusted EBITDA Summary Full year 2024 Adjusted EBITDA reached $8.5 million, up $6.6 million YoY, driven by higher net income, partially offset by lower share-based compensation expense, reversed royalties & fees and recovered credit losses. ChromaDex Corporation and Subsidiaries Reconciliation o
Slide 12: Q4 2024 Operating Loss vs Q4 2023
12 Q4 2024 Operating Loss vs Q4 2023 (0.2) (2.2) (0.2) 4.8 4.1 0.4 0.2 0.2 7.1 Q4 2023 Operating Loss Sales & Marketing Research & Development Volume Other G&A (1) Gross Margin Improvement Equity Comp (G&A) Legal Q4 2024 Operating Income (4.0) MM (3.0) MM (2.0) MM (1.0) MM 0.0 MM 1.0 MM 2.0 MM 3.0 M
Slide 13: Balance Sheet Highlights
13 Balance Sheet Highlights Highlights effective execution of strategic priorities, resulting in a stronger balance sheet with improved liquidity, reduced inventory, and enhanced receivables, all while maintaining disciplined cost management to support long-term growth. (in thousands) 12/31/23 3/31/
Slide 14: Cash Flow Highlights
14 Cash Flow Highlights (in thousands) FY 2023 3/31/24 6/30/24 9/30/24 12/31/24 FY 2024 Net Income (Loss) $(4,938) $(492) $(15) $1,878 $7,179 $8,550 Working Capital 5,206 (643) (1,837) 1,235 5,111 3,866 Cash From / (Used for) Operations 7,117 295 (264) 3,495 8,583 12,109 Cash Used for Investing (143
Slide 15: 2024 Full Year Outlook Recap
15 2024 Full Year Outlook Recap (in thousands) 2023 Actual 2024 Outlook (1) 2024 Actual Comments Achieved?(2) Net Sales $83,570 Approximately 15% growth YoY $99,597 Total net sales grew by +19% ü Gross Margin % (as a % of net sales) 60.8% Slight improvement YoY 61.8% Improved 100 bps ü Selling, Mark
Slide 16: 2025 Full Year Outlook
16 (in thousands) 2024 Actual 2025 Full Year Outlook Key Drivers Net Sales $99,597 Approximately 18% growth YoY • Includes growth from e-commerce business and recurring revenues from established partnerships. • Includes revenues from new partnerships, and revenue growth in the pharmaceutical grade i
Slide 17: The Science
The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) The Science 17
Slide 18: Scientific Advisory Board
18 Scientific Advisory Board Charles Brenner, Ph.D. Alfred E Mann Family Foundation Chair, Department of Diabetes & Cancer Metabolism City of Hope World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.D. Chairman Professor of Structural Biology Stanford University Nobel Prize Winner, Chemi
Slide 19: Clinical Studies on Niagen® in Multiple Health Areas
19 Clinical Studies on Niagen® in Multiple Health Areas Note: highlighted achievements in duration, participation and dosage only consider completed studies. Status of clinical studies presented as of 2/18/2025.
Slide 20: Contact Info
20 Contact Info: Ben Shamsian Lytham Partners T: +1(646) 829-9701 Shamsian@LythamPartners.com www.ChromaDex.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com